Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 526

1.

Genomic profiling of blood-derived circulating tumor DNA from patients with colorectal cancer: Implications for response and resistance to targeted therapeutics.

Choi IS, Kato S, Fanta PT, Leichman L, Okamura R, Raymond VM, Lanman RB, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2019 Jul 18. pii: molcanther.0965.2018. doi: 10.1158/1535-7163.MCT-18-0965. [Epub ahead of print]

PMID:
31320401
2.

Metformin inhibits progression of Head and Neck Squamous Cell Carcinoma by acting Directly on Carcinoma Initiating Cells.

Wu X, Yeerna H, Goto Y, Ando T, Wu VH, Zhang X, Wang Z, Amornphimoltham P, Murphy AN, Tamayo P, Chen Q, Lippman SM, Gutkind JS.

Cancer Res. 2019 Jul 10. pii: canres.3525.2018. doi: 10.1158/0008-5472.CAN-18-3525. [Epub ahead of print]

PMID:
31292160
3.

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies.

Kato S, Okamura R, Mareboina M, Lee S, Goodman A, Patel SP, Fanta PT, Schwab RB, Vu P, Raymond VM, Lanman RB, Sicklick JK, Lippman SM, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00180. Epub 2019 Jan 22.

4.

Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival.

Kato S, Schwaederlé MC, Fanta PT, Okamura R, Leichman L, Lippman SM, Lanman RB, Raymond VM, Talasaz A, Kurzrock R.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00158. Epub 2019 Jan 25.

5.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
6.

4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.

Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X, Gilardi M, Allevato M, Wu V, Steffen DJ, Tofilon P, Sonenberg N, Califano J, Chen Q, Lippman SM, Gutkind JS.

Cancer Res. 2019 Apr 1;79(7):1438-1450. doi: 10.1158/0008-5472.CAN-18-1220. Epub 2019 Mar 20.

PMID:
30894372
7.

Waun Ki Hong (1942-2019) John Mendelsohn (1936-2019).

Lippman SM, Kurzrock R.

Cancer Cell. 2019 Feb 11;35(2):157-160. doi: 10.1016/j.ccell.2019.01.014. Epub 2019 Feb 11. No abstract available.

8.

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer.

Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H.

Cancer Res. 2019 Feb 15;79(4):689-698. doi: 10.1158/0008-5472.CAN-18-1281. Epub 2019 Feb 4. Review.

PMID:
30718357
9.

Immunological and classical subtypes of oral premalignant lesions.

Foy JP, Bertolus C, Ortiz-Cuaran S, Albaret MA, Williams WN, Lang W, Destandau S, Souza G, Sohier E, Kielbassa J, Thomas E, Deneuve S, Goudot P, Puisieux A, Viari A, Mao L, Caux C, Lippman SM, Saintigny P.

Oncoimmunology. 2018 Sep 21;7(12):e1496880. doi: 10.1080/2162402X.2018.1496880. eCollection 2018.

10.

AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health.

Lippman SM, Abate-Shen C, Colbert Maresso KL, Colditz GA, Dannenberg AJ, Davidson NE, Disis ML, DuBois RN, Szabo E, Giuliano AR, Hait WN, Lee JJ, Kensler TW, Kramer BS, Limburg P, Maitra A, Martinez ME, Rebbeck TR, Schmitz KH, Vilar E, Hawk ET.

Cancer Prev Res (Phila). 2018 Dec;11(12):735-778. doi: 10.1158/1940-6207.CAPR-18-0421.

PMID:
30530635
11.

Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial.

Day TA, Shirai K, O'Brien PE, Matheus MG, Godwin K, Sood AJ, Kompelli A, Vick JA, Martin D, Vitale-Cross L, Callejas-Varela JL, Wang Z, Wu X, Harismendy O, Molinolo AA, Lippman SM, Van Waes C, Szabo E, Gutkind JS.

Clin Cancer Res. 2019 Feb 15;25(4):1156-1164. doi: 10.1158/1078-0432.CCR-18-2024. Epub 2018 Nov 12.

PMID:
30420444
12.

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.

Kato S, Okamura R, Baumgartner JM, Patel H, Leichman L, Kelly K, Sicklick JK, Fanta PT, Lippman SM, Kurzrock R.

Clin Cancer Res. 2018 Dec 15;24(24):6248-6256. doi: 10.1158/1078-0432.CCR-18-1128. Epub 2018 Oct 22.

PMID:
30348637
13.

Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer.

Goggins MG, Lippman SM, Constantinou PE, Jacks T, Petersen GM, Syngal S, Maitra A.

Pancreas. 2018 Nov/Dec;47(10):1175-1176. doi: 10.1097/MPA.0000000000001165. No abstract available.

PMID:
30325853
14.

Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients.

Pierzynski JA, Ye Y, Lippman SM, Rodriguez MA, Wu X, Hildebrandt MAT.

Sci Rep. 2018 Jul 13;8(1):10640. doi: 10.1038/s41598-018-25712-1.

15.

Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.

Martin D, Degese MS, Vitale-Cross L, Iglesias-Bartolome R, Valera JLC, Wang Z, Feng X, Yeerna H, Vadmal V, Moroishi T, Thorne RF, Zaida M, Siegele B, Cheong SC, Molinolo AA, Samuels Y, Tamayo P, Guan KL, Lippman SM, Lyons JG, Gutkind JS.

Nat Commun. 2018 Jul 9;9(1):2372. doi: 10.1038/s41467-018-04590-1.

16.

The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K.

Zhang T, Wang Q, Fredimoses M, Gao G, Wang K, Chen H, Wang T, Oi N, Zykova TA, Reddy K, Yao K, Ma W, Chang X, Lee MH, Rathore MG, Bode AM, Ashida H, Lippman SM, Dong Z.

Cancer Prev Res (Phila). 2018 Oct;11(10):607-620. doi: 10.1158/1940-6207.CAPR-18-0092. Epub 2018 Jul 6.

PMID:
29980517
17.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

18.

Positive Surgical Margins in the 10 Most Common Solid Cancers.

Orosco RK, Tapia VJ, Califano JA, Clary B, Cohen EEW, Kane C, Lippman SM, Messer K, Molinolo A, Murphy JD, Pang J, Sacco A, Tringale KR, Wallace A, Nguyen QT.

Sci Rep. 2018 Apr 9;8(1):5686. doi: 10.1038/s41598-018-23403-5.

19.

Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer.

Saintigny P, William WN Jr, Foy JP, Papadimitrakopoulou V, Lang W, Zhang L, Fan YH, Feng L, Kim ES, El-Naggar AK, Lee JJ, Mao L, Hong WK, Lingen MW, Lippman SM.

J Natl Cancer Inst. 2018 Mar 1;110(3). doi: 10.1093/jnci/djx186.

20.

Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I-IIIA lung cancer.

Ha D, Ries AL, Mazzone PJ, Lippman SM, Fuster MM.

Support Care Cancer. 2018 Jul;26(7):2459-2469. doi: 10.1007/s00520-018-4078-4. Epub 2018 Feb 10.

21.

Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.

Deng Y, Tu H, Pierzynski JA, Miller ED, Gu X, Huang M, Chang DW, Ye Y, Hildebrandt MAT, Klein AP, Zhao R, Lippman SM, Wu X.

Eur J Cancer. 2018 Mar;92:20-32. doi: 10.1016/j.ejca.2017.12.023. Epub 2018 Feb 3.

PMID:
29413686
22.

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.

23.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

24.

Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence.

Kerr J, Anderson C, Lippman SM.

Lancet Oncol. 2017 Aug;18(8):e457-e471. doi: 10.1016/S1470-2045(17)30411-4. Epub 2017 Jul 26. Review.

PMID:
28759385
25.

A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts.

Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, Lucia MS, Klein EA, Lippman SM, Parnes HL, Thompson IM, Goodman PJ, Tangen CM, De Marzo AM.

Cancer Epidemiol Biomarkers Prev. 2017 Oct;26(10):1549-1557. doi: 10.1158/1055-9965.EPI-17-0503. Epub 2017 Jul 28.

26.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

27.

Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology.

Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2017 May;16(5):948-955. doi: 10.1158/1535-7163.MCT-16-0436.

28.

Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.

Dasanu CA, Alvarez-Argote J, Lippman SM, Plaxe SC.

J Oncol Pharm Pract. 2018 Apr;24(3):229-231. doi: 10.1177/1078155217698845. Epub 2017 Mar 12.

PMID:
28436313
29.

Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.

Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R.

Clin Cancer Res. 2017 Aug 15;23(16):4716-4723. doi: 10.1158/1078-0432.CCR-17-0454. Epub 2017 Apr 18.

30.

Precancer Atlas to Drive Precision Prevention Trials.

Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, Giannakis M, Shilatifard A, Finn OJ, Dhodapkar M, Kay NE, Braggio E, Vilar E, Mazzilli SA, Rebbeck TR, Garber JE, Velculescu VE, Disis ML, Wallace DC, Lippman SM.

Cancer Res. 2017 Apr 1;77(7):1510-1541. doi: 10.1158/0008-5472.CAN-16-2346.

31.

Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial.

Winchester DA, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Xu J, Zheng SL, Thompson IM, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, De Marzo AM, Drake CG, Platz EA.

Prostate. 2017 Jun;77(8):908-919. doi: 10.1002/pros.23346. Epub 2017 Mar 20.

32.

Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer.

Carter H, Marty R, Hofree M, Gross AM, Jensen J, Fisch KM, Wu X, DeBoever C, Van Nostrand EL, Song Y, Wheeler E, Kreisberg JF, Lippman SM, Yeo GW, Gutkind JS, Ideker T.

Cancer Discov. 2017 Apr;7(4):410-423. doi: 10.1158/2159-8290.CD-16-1045. Epub 2017 Feb 10.

33.

Translating Germline Cancer Risk into Precision Prevention.

Yurgelun MB, Chenevix-Trench G, Lippman SM.

Cell. 2017 Feb 9;168(4):566-570. doi: 10.1016/j.cell.2017.01.031.

34.

Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma.

Krishnan AR, Korrapati A, Zou AE, Qu Y, Wang XQ, Califano JA, Wang-Rodriguez J, Lippman SM, Hovell MF, Ongkeko WM.

Oral Oncol. 2017 Feb;65:68-75. doi: 10.1016/j.oraloncology.2016.12.022. Epub 2016 Dec 31.

35.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank.

McCaskill-Stevens W, Pearson DC, Kramer BS, Ford LG, Lippman SM.

Cancer Prev Res (Phila). 2017 Feb;10(2):99-107. doi: 10.1158/1940-6207.CAPR-16-0230. Epub 2016 Dec 13. Review.

36.

Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer.

Dasanu CA, Lippman SM, Plaxe SC.

J Oncol Pharm Pract. 2017 Dec;23(8):638-640. doi: 10.1177/1078155216674355. Epub 2016 Oct 18.

PMID:
27824586
37.

Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan.

Wu X, Wen CP, Ye Y, Tsai M, Wen C, Roth JA, Pu X, Chow WH, Huff C, Cunningham S, Huang M, Wu S, Tsao CK, Gu J, Lippman SM.

Sci Rep. 2016 Nov 2;6:36482. doi: 10.1038/srep36482.

38.

Sleep and Breathing … and Cancer?

Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Dannenberg AJ, Lippman SM, Malhotra A; UCSD Sleep and Cancer Symposium Group.

Cancer Prev Res (Phila). 2016 Nov;9(11):821-827. Epub 2016 Sep 7. Review. Erratum in: Cancer Prev Res (Phila). 2017 Jan;10 (1):98.

39.

Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize.

Adams SR, Yang HC, Savariar EN, Aguilera J, Crisp JL, Jones KA, Whitney MA, Lippman SM, Cohen EE, Tsien RY, Advani SJ.

Nat Commun. 2016 Oct 4;7:13019. doi: 10.1038/ncomms13019.

40.

Leveraging premalignant biology for immune-based cancer prevention.

Spira A, Disis ML, Schiller JT, Vilar E, Rebbeck TR, Bejar R, Ideker T, Arts J, Yurgelun MB, Mesirov JP, Rao A, Garber J, Jaffee EM, Lippman SM.

Proc Natl Acad Sci U S A. 2016 Sep 27;113(39):10750-8. doi: 10.1073/pnas.1608077113. Epub 2016 Sep 16.

41.

The non-coding landscape of head and neck squamous cell carcinoma.

Zou AE, Zheng H, Saad MA, Rahimy M, Ku J, Kuo SZ, Honda TK, Wang-Rodriguez J, Xuan Y, Korrapati A, Yu V, Singh P, Grandis JR, King CC, Lippman SM, Wang XQ, Hinton A, Ongkeko WM.

Oncotarget. 2016 Aug 9;7(32):51211-51222. doi: 10.18632/oncotarget.9979.

42.

Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer.

Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ, Troncoso P.

EBioMedicine. 2016 May;7:85-93. doi: 10.1016/j.ebiom.2016.03.047. Epub 2016 Apr 7.

43.

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer.

Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N.

Breast Cancer Res Treat. 2016 Jul;158(1):67-77. doi: 10.1007/s10549-016-3849-1. Epub 2016 Jun 10.

44.

The Conundrum of Genetic "Drivers" in Benign Conditions.

Kato S, Lippman SM, Flaherty KT, Kurzrock R.

J Natl Cancer Inst. 2016 Apr 7;108(8). pii: djw036. doi: 10.1093/jnci/djw036. Print 2016 Aug. Review.

45.

The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer.

Foy JP, Tortereau A, Caulin C, Le Texier V, Lavergne E, Thomas E, Chabaud S, Perol D, Lachuer J, Lang W, Hong WK, Goudot P, Lippman SM, Bertolus C, Saintigny P.

Oncotarget. 2016 Jun 14;7(24):35932-35945. doi: 10.18632/oncotarget.8321.

46.

Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress.

Guertin KA, Grant RK, Arnold KB, Burwell L, Hartline J, Goodman PJ, Minasian LM, Lippman SM, Klein E, Cassano PA.

Free Radic Biol Med. 2016 Jun;95:349-56. doi: 10.1016/j.freeradbiomed.2016.03.010. Epub 2016 Mar 22.

47.

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.

Yamaguchi K, Iglesias-Bartolomé R, Wang Z, Callejas-Valera JL, Amornphimoltham P, Molinolo AA, Cohen EE, Califano JA, Lippman SM, Luo J, Gutkind JS.

Oncotarget. 2016 Mar 8;7(10):10696-709. doi: 10.18632/oncotarget.7372.

48.

Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience.

Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, Helsten TL, Bazhenova LA, Romero J, Fanta PT, Lippman SM, Kurzrock R.

Mol Cancer Ther. 2016 Apr;15(4):743-52. doi: 10.1158/1535-7163.MCT-15-0795. Epub 2016 Feb 12.

49.

Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial.

Winchester DA, Gurel B, Till C, Goodman PJ, Tangen CM, Santella RM, Johnson-Pais TL, Leach RJ, Thompson IM, Xu J, Zheng SL, Lucia MS, Lippman SM, Parnes HL, Isaacs WB, Drake CG, De Marzo AM, Platz EA.

Prostate. 2016 May;76(6):565-74. doi: 10.1002/pros.23147. Epub 2016 Jan 15.

50.

Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, Dannenberg AJ, Hait WN, Blackburn E, Davidson NE, Foti M, Lippman SM.

Cancer Prev Res (Phila). 2016 Jan;9(1):2-10. doi: 10.1158/1940-6207.CAPR-15-0406.

Supplemental Content

Loading ...
Support Center